Current Rating and Its Implications
MarketsMOJO’s Strong Sell rating on Hikal Ltd indicates a cautious stance for investors, signalling significant concerns about the company’s near- and long-term prospects. This rating suggests that investors should consider avoiding new positions or potentially reducing existing holdings, given the prevailing challenges in the company’s fundamentals, valuation, financial trends, and technical outlook. The rating is derived from a comprehensive assessment of these four key parameters, each of which is critical in understanding the stock’s current risk and return profile.
Quality Assessment: Below Average Fundamentals
As of 25 December 2025, Hikal Ltd’s quality grade remains below average, reflecting weak long-term fundamental strength. The company has experienced a compound annual growth rate (CAGR) decline of -16.24% in operating profits over the past five years, signalling deteriorating operational efficiency and profitability. Additionally, the average return on equity (ROE) stands at a modest 8.00%, indicating limited profitability generated per unit of shareholders’ funds. This level of ROE is generally considered low for a pharmaceutical and biotechnology firm, where higher returns are expected due to the sector’s innovation-driven nature.
Moreover, the company’s ability to service debt is constrained, with a high Debt to EBITDA ratio of 2.51 times. This elevated leverage ratio raises concerns about financial flexibility and the capacity to withstand adverse market conditions or invest in growth initiatives. Collectively, these factors contribute to the below-average quality grade and underpin the cautious rating.
Register here to know the latest call on Hikal Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Valuation: Attractive but Reflective of Risks
Despite the challenges, Hikal Ltd’s valuation grade is currently attractive. This suggests that the stock is trading at a relatively low price compared to its earnings, book value, or cash flow metrics. Such valuation levels often reflect market concerns about the company’s financial health and growth prospects. For value-oriented investors, this could present a potential entry point, but only if the underlying issues are addressed or if a turnaround becomes evident.
It is important to note that an attractive valuation alone does not guarantee positive returns, especially when fundamental and financial trends are weak. Investors should weigh the valuation against the company’s operational and financial challenges before making investment decisions.
Financial Trend: Very Negative Performance Indicators
The financial grade for Hikal Ltd is very negative as of 25 December 2025, reflecting deteriorating earnings and sales performance. The company reported a sharp fall in earnings per share (EPS) by -320.54% in the September 2025 quarter, accompanied by negative net profits for two consecutive quarters. Quarterly net sales have declined by -30.5% compared to the previous four-quarter average, with net profit after tax (PAT) at a loss of ₹34.90 crores, down by -320.5% relative to the same period.
Return on capital employed (ROCE) for the half-year ended September 2025 is at a low 4.44%, underscoring inefficient capital utilisation. These financial trends highlight significant operational stress and weak profitability, which weigh heavily on the stock’s outlook and justify the Strong Sell rating.
Technical Outlook: Mildly Bearish Momentum
From a technical perspective, Hikal Ltd’s stock exhibits mildly bearish signals. The share price has declined by -1.49% on the most recent trading day and has delivered negative returns over the medium to long term. Specifically, the stock has fallen -36.19% over the past year and -34.99% over the last six months. It has also underperformed the BSE500 index across one year, three years, and three months, indicating weak relative strength.
While there was a modest 9.40% gain in the last month, this short-term uptick is insufficient to offset the broader downtrend. The mildly bearish technical grade suggests that the stock may continue to face selling pressure unless there is a significant change in fundamentals or market sentiment.
Stock Returns and Market Performance
As of 25 December 2025, Hikal Ltd’s stock returns paint a challenging picture for investors. The year-to-date (YTD) return stands at -38.76%, with a one-year return of -36.19%. Over the last six months, the stock has declined by -34.99%, while the three-month return is -8.12%. These figures indicate sustained underperformance relative to broader market indices and sector peers.
The stock’s small-cap status within the Pharmaceuticals & Biotechnology sector adds to its volatility and risk profile, making it more susceptible to market fluctuations and company-specific developments.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
What This Rating Means for Investors
The Strong Sell rating on Hikal Ltd serves as a clear caution to investors. It reflects a consensus view that the company currently faces significant operational and financial headwinds, which are unlikely to be resolved in the near term. Investors should be wary of initiating new positions and consider the risks of holding existing shares, especially given the company’s weak profitability, high leverage, and negative earnings trends.
For long-term investors, the stock’s attractive valuation may warrant monitoring for signs of a turnaround or improvement in fundamentals. However, until such evidence emerges, the prudent approach is to maintain a defensive stance. The mildly bearish technical signals further reinforce the need for caution, as the stock price may continue to face downward pressure.
In summary, the Strong Sell rating is grounded in a holistic analysis of quality, valuation, financial trends, and technical factors, all of which currently point to a challenging outlook for Hikal Ltd.
Company Profile and Market Context
Hikal Ltd operates within the Pharmaceuticals & Biotechnology sector as a small-cap company. The sector is known for its innovation-driven growth potential but also for volatility linked to regulatory approvals, research outcomes, and competitive pressures. Hikal’s current struggles highlight the difficulties faced by smaller players in maintaining profitability and growth amid these sector dynamics.
Investors should consider the broader industry trends and peer performance when evaluating Hikal Ltd, as sector tailwinds or headwinds can materially impact the company’s prospects.
Summary of Key Metrics as of 25 December 2025
- Mojo Score: 17.0 (Strong Sell)
- Market Capitalisation: Small Cap
- Operating Profit CAGR (5 years): -16.24%
- Debt to EBITDA Ratio: 2.51 times
- Average Return on Equity: 8.00%
- EPS Decline (Sep 2025 quarter): -320.54%
- Net Sales (Quarterly): ₹318.50 crores, down -30.5%
- Profit After Tax (Quarterly): ₹-34.90 crores, down -320.5%
- ROCE (Half Year): 4.44%
- Stock Returns: 1Y -36.19%, YTD -38.76%, 6M -34.99%
These metrics collectively underpin the current Strong Sell rating and provide a comprehensive view of the company’s financial health and market performance.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
